Heart Failure

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

Heart failure higher among RA patients independent of their risk for ischemic heart disease.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.

Physical inactivity and weight gain may increase the risk of heart failure with preserved ejection fraction.

A porcupine inhibitor may regenerate heart tissue after a heart attack and prevent heart failure.

Stress may increase brain activity and lead to inflammation of the heart.

A cardiac lipid panel test plus a NT-proBNP test may be able to diagnose heart failure early.

EZR-201 combines an angiotensin receptor blocker, valsartan, with Rubireten delivery technology for the treatment of hypertension and heart failure.

The FDA has accepted the new drug application (NDA) for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure.

In this clip, Dr. Peter Salgo, a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital discusses heart failure.

The costs of generic heart failure medications can vary by hundreds of dollars.

Treatment with Entresto was associated with a reduction in hospitalization and death up to 24% in patients with heart failure.

An initiative that lowered copays for prescription drugs also lowered hospitalizations by 40%

Type 2 diabetes patients struggle with high blood glucose levels that can damage nerves and blood vessels, factors that could trigger heart attacks.

Low health literacy, financial instability, and lack of social support promote poor adherence.

Poor medication adherence contributes to 125,000 deaths annually, causes up to half of all treatment failures, and costs the US healthcare system $100 billion each year.

Heart failure patients are much more likely to have diabetes than the general population.

The incidence of heart failure is increasing as the world's population ages and the rates of other, often comorbid, diseases (eg, diabetes, heart disease, obesity) increase.

This article summarizes recent literature surrounding the use of tolvaptan for acute heart failure.

That is, are they all equally effective?

The toxicity of cancer drugs increasingly causing cardiovascular complications in patients.

No difference found in mortality and cardiac events among patients that were and were not taking beta-blockers after an angioplasty.

Supplemental coenzyme Q10 may be a management option for patients with heart failure.

The FDA has approved Silvergate Pharmaceuticals' Qbrelis, the first lisinopril oral solution.

Heart failure with preserved ejection typically accompanied by hypertension, diabetes, lung disease, or chronic renal failure.

Top news of the day from across the health care landscape.

This article highlights the latest literature surrounding both new and old heart failure therapies.

Approximately 12.3% of patients diagnosed with heart failure were diagnosed with cancer.